C4 Therapeutics, Inc. (CCCC) financial statements and ratios from SEC XBRL: revenue $35.95M (TTM), net margin -292.1%, revenue growth 1.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $35.95M |
| Net Margin | -292.1% |
| Revenue Growth (YoY) | 1.0% |
| EPS Growth (YoY) | -16.4% |
| FCF Growth (YoY) | 52.0% |
| Price / Book | 1.99 |
| Price / Sales | 16.31 |
| FCF Yield | -34.3% |
| Altman Z-Score | -0.80 (distress) |
| Sector P/E (Healthcare) | 21.7 |
CCCC overview · CCCC earnings · CCCC KPIs · CCCC investor relations · CCCC ownership · CCCC peers · CCCC filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.